Literature DB >> 3494760

Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection.

M Pignatelli, J Waters, A Lever, S Iwarson, R Gerety, H C Thomas.   

Abstract

The nucleocapsid antigens (HBc and HBe) are present on the membranes of HBV-infected hepatocytes from HBV carriers. In autologous cytotoxicity experiments we demonstrate that cytotoxic T cells sensitised to the nucleocapsid proteins of hepatitis B are present in HBe antigen-positive HBV carriers with chronic hepatitis and can be blocked by monoclonal anti-HBc and anti-HBe. Passive immunisation of chimpanzees with monoclonal anti-HBc and anti-HBe offers no protection against HBV infection but in both cases leads to an unusually prolonged hepatitis probably by modulation of HBc and HBe antigen display on the hepatocytes. High-titre anti-HBc in the circulation of HBe antigen-positive patients probably modulates the former protein making HBe the important target antigen for cytotoxic T cells mediating liver damage in chronic carriers. These data also support the hypothesis that passive transfer of IgG anti-HBc across the placenta may be one major factor promoting development of persistent infection in neonates infected from carrier mothers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494760     DOI: 10.1016/s0168-8278(87)80004-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  26 in total

1.  Hepatitis B virus p25 precore protein accumulates in Xenopus oocytes as an untranslocated phosphoprotein with an uncleaved signal peptide.

Authors:  S Q Yang; M Walter; D N Standring
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 2.  The cellular immune response to nucleocapsid antigens in hepatitis B virus infection.

Authors:  M U Mondelli; F V Chisari; C Ferrari
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Cellular immunity to nucleocapsid and pre-S determinants in asymptomatic carriers of hepatitis B virus.

Authors:  S Vento; S H Chen; G Giuliani-Piccari; C J O'Brien; P R Dal Monte; A L Eddleston; C R Howard; R Williams
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

4.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

Authors:  D R Milich; J E Jones; J L Hughes; J Price; A K Raney; A McLachlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 5.  Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus.

Authors:  N V Naoumov; A L Eddleston
Journal:  Gut       Date:  1994-08       Impact factor: 23.059

6.  Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection.

Authors:  A Nagasaka; S Hige; M Marutani; I Tsunematsu; M Saito; Y Yamamoto; S Konishi; M Asaka
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

7.  Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.

Authors:  A S Lok; U Akarca; S Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Cytotoxic T lymphocyte activity to hepatitis B virus DNA-transfected HepG2 cells in patients with chronic hepatitis B.

Authors:  Y Ito; S Kakumu; K Yoshioka; T Wakita; T Ishikawa; K Koike
Journal:  Gastroenterol Jpn       Date:  1993-10

9.  Immunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis.

Authors:  C M Chu; Y F Liaw
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

10.  Protein composition of the hepatitis B virus e antigen in the natural course of disease and following interferon therapy.

Authors:  M L Campillo; J A Quiroga; J Bartolomé; G Moraleda; I Castillo; V Carreño
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.